Skip to main content

luspatercept (Reblozyl®)

 

Following non-submission

AWMSG advice

Status: Not endorsed (Statement of Advice)

In the absence of a submission from the holder of the marketing authorisation, luspatercept (Reblozyl®) cannot be endorsed for use within NHS Wales for treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy and for the treatment of adult patients with transfusion-dependent anaemia associated with beta-thalassaemia.

 Statement of Advice (SOA): luspatercept (Reblozyl) 2177 (PDF, 88Kb)

Medicine details

Medicine name luspatercept (Reblozyl®)
Formulation 25 mg powder for solution for injection, 75 mg powder for solution for injection
Reference number 2177
Indication

Treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy and for the treatment of adult patients with transfusion-dependent anaemia associated with beta-thalassaemia

Company Celgene Ltd
BNF chapter Malignant disease & immunosuppression
Submission type Non-submission
Status Not endorsed (Statement of Advice)
Date of issue 02/02/2021